Ultragenyx Pharmaceutical, Inc. (RARE)
14.30
-0.10
(-0.69%)
USD |
NASDAQ |
Sep 11, 16:00
14.30
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Profit Margin (Quarterly) : -42.99% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -42.99% |
| March 31, 2026 | -136.0% |
| December 31, 2025 | -62.32% |
| September 30, 2025 | -112.8% |
| June 30, 2025 | -69.04% |
| March 31, 2025 | -108.5% |
| December 31, 2024 | -80.90% |
| September 30, 2024 | -95.71% |
| June 30, 2024 | -89.51% |
| March 31, 2024 | -156.8% |
| December 31, 2023 | -96.70% |
| September 30, 2023 | -162.8% |
| June 30, 2023 | -147.6% |
| March 31, 2023 | -163.2% |
| December 31, 2022 | -146.9% |
| September 30, 2022 | -270.2% |
| June 30, 2022 | -177.0% |
| March 31, 2022 | -190.6% |
| December 31, 2021 | -146.9% |
| September 30, 2021 | -89.41% |
| June 30, 2021 | -140.8% |
| Date | Value |
|---|---|
| March 31, 2021 | -137.0% |
| December 31, 2020 | -26.23% |
| September 30, 2020 | -84.50% |
| June 30, 2020 | 41.02% |
| March 31, 2020 | -327.8% |
| December 31, 2019 | -263.5% |
| September 30, 2019 | -438.0% |
| June 30, 2019 | -410.7% |
| March 31, 2019 | -532.4% |
| December 31, 2018 | -540.1% |
| September 30, 2018 | -742.2% |
| June 30, 2018 | -412.1% |
| March 31, 2018 | |
| December 31, 2017 | -3.39K% |
| September 30, 2017 | -40.01K% |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | -1.43M% |
| September 30, 2016 | -58.47K% |
| June 30, 2016 | -334.8K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| AbbVie, Inc. | 21.21% |
| Biogen, Inc. | 3.72% |
| BioMarin Pharmaceutical, Inc. | 4.49% |
| Ionis Pharmaceuticals, Inc. | -42.79% |
| Regeneron Pharmaceuticals, Inc. | 30.23% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -44.50% |
| Return on Invested Capital | -58.78% |
| Gross Profit Margin (Quarterly) | 80.37% |
| Operating Margin (Quarterly) | -35.05% |
| Return on Net Operating Assets | -88.37% |